Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy

ACS Nano. 2024 Jan 23;18(3):1846-1864. doi: 10.1021/acsnano.3c11260. Epub 2024 Jan 5.

Abstract

Mutation burden, hypoxia, and immunoediting contribute to altered metabolic profiles in tumor cells, resulting in a tumor microenvironment (TME) characterized by accumulation of toxic metabolites and depletion of various nutrients, which significantly hinder the antitumor immunity via multiple mechanisms, hindering the efficacy of tumor immunotherapies. In-depth investigation of the mechanisms underlying these phenomena are vital for developing effective antitumor drugs and therapies, while the therapeutic effects of metabolism-targeting drugs are restricted by off-target toxicity toward effector immune cells and high dosage-mediated side effects. Nanotechnologies, which exhibit versatility and plasticity in targeted delivery and metabolism modulation, have been widely applied to boost tumor immunometabolic therapies via multiple strategies, including targeting of metabolic pathways. In this review, recent advances in understanding the roles of tumor cell metabolism in both immunoevasion and immunosuppression are reviewed, and nanotechnology-based metabolic reprogramming strategies for enhanced tumor immunotherapies are discussed.

Keywords: Adaptive immunity; Innate immunity; Metabolism; Metabolites; Nanotechnology; Tumor heterogenicity; Tumor immunotherapy; Tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Humans
  • Immunosuppression Therapy
  • Immunotherapy / methods
  • Nanotechnology
  • Neoplasms* / drug therapy
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents